Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review

International Journal of Radiation Oncology Biology Physics

Volumn 98, Issue 3, 2017, Pages 622-631

  Chen, Hanbo ^a   Senan, Suresh ^b   Nossent, Esther J ^b   Boldt, R Gabriel ^a   Warner, Andrew ^a   Palma, David A ^a   Louie, Alexander V ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DISEASE CONTROL; PARTICLE BEAMS; PATIENT MONITORING; PULMONARY DISEASES; RADIOTHERAPY; SURGERY; TOXICITY;

DEFINITIVE THERAPY; DOSIMETRIC PARAMETER; INTERSTITIAL LUNG DISEASE; MEDICALLY INOPERABLE; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; RADIOFREQUENCY ABLATION; SYSTEMATIC REVIEW;

DIAGNOSIS;

BEAM THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DOSIMETRY; EARLY CANCER; EMBASE; FIBROSING ALVEOLITIS; HUMAN; IATROGENIC DISEASE; INOPERABLE CANCER; INTERSTITIAL LUNG DISEASE; LUNG; MEDLINE; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OLIGOMETASTASIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOFREQUENCY ABLATION; RADIOTHERAPY DOSAGE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL ANALYSIS; SYSTEMATIC REVIEW; TOXICITY; TREATMENT RELATED TOXICITY; TREND STUDY; TUMOR ABLATION; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; COMPLICATION; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PATHOLOGY; PULMONARY FIBROSIS; RADIOSURGERY;

CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PULMONARY FIBROSIS; RADIOSURGERY; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 85026288419     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2017.03.010     Document Type: Review

References (77)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. Molina, J.R., Yang, P., Cassivi, S.D., et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83 (2008), 584–594.
3. Cancer of the Lung and Bronchus - SEER Stat Fact Sheets, 2016 Available at: http://seer.cancer.gov/statfacts/html/lungb.html Accessed July 23, 2016.
4. Vansteenkiste, J., Crino, L., Dooms, C., et al. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 25 (2014), 1462–1474.
5. Howington, J.A., Blum, M.G., Chang, A.C., et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (2013), e278S–e313.
6. Louie, A.V., Rodrigues, G.B., Palma, D.A., et al. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. Oncologist 19 (2014), 880–885.
7. Taremi, M., Hope, A., Dahele, M., et al. Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 82 (2012), 967–973.
8. Chang, J.Y., Liu, H., Balter, P., et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol, 7, 2012, 152.
9. Crabtree, T., Puri, V., Timmerman, R., et al. Treatment of stage I lung cancer in high-risk and inoperable patients: Comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 145 (2013), 692–699.
10. Demedts, M., Costabel, U., ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 19 (2002), 794–796.
11. Bradley, B., Branley, H.M., Egan, J.J., et al. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 68 (2008), v1–v58.
12. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ, 339, 2009, b2535.
13. Hara, Y., Takeda, A., Eriguchi, T., et al. Stereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapy. J Radiat Res 57 (2016), 62–67.
14. Yoshitake, T., Shioyama, Y., Asai, K., et al. Impact of interstitial changes on radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Anticancer Res 35 (2015), 4909–4913.
15. Jung, I.H., Song, S.Y., Jung, J., et al. Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer. Radiat Oncol J 33 (2015), 89–97.
16. Ueki, N., Matsuo, Y., Togashi, Y., et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 10 (2015), 116–125.
17. Shintani, T., Masago, K., Takayama, K., et al. Stereotactic body radiotherapy for synchronous primary lung cancer: Clinical outcome of 18 cases. Clin Lung Cancer 16 (2015), e91–e96.
18. Bahig, H., Filion, E., Vu, T., et al. Excellent cancer outcomes following patient-adapted robotic lung SBRT but a case for caution in idiopathic pulmonary fibrosis. Technol Cancer Res Treat 14 (2015), 667–676.
19. Thibault, I., Poon, I., Yeung, L., et al. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: A single institution's comprehensive experience. Clin Oncol (R Coll Radiol) 26 (2014), 713–719.
20. Aibe, N., Yamazaki, H., Nakamura, S., et al. Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: Analysis of grade 5 radiation pneumonitis. J Radiat Res 55 (2014), 575–582.
21. Yamaguchi, S., Ohguri, T., Ide, S., et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis. Lung Cancer 82 (2013), 260–265.
22. Takeda, A., Sanuki, N., Eriguchi, T., et al. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86 (2013), 257–263.
23. Yamashita, H., Kobayashi-Shibata, S., Terahara, A., et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol, 5, 2010, 32.
24. Takeda, A., Enomoto, T., Sanuki, N., et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med 26 (2008), 504–507.
25. Timmerman, R., Papiez, L., McGarry, R., et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124 (2003), 1946–1955.
26. Westover, K.D., Seco, J., Adams, J.A., et al. Proton SBRT for medically inoperable stage I NSCLC. J Thorac Oncol 7 (2012), 1021–1025.
27. Ono, T., Hareyama, M., Nakamura, T., et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: A single center experience. Radiat Oncol, 11, 2016, 56.
28. Nakayama, H., Sugahara, S., Tokita, M., et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the University of Tsukuba. Int J Radiat Oncol Biol Phys 78 (2010), 467–471.
29. Miyamoto, T., Yamamoto, N., Nishimura, H., et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 66 (2003), 127–140.
30. Okuma, T., Tsuji, T., Sakamoto, T., et al. A case of postoperative pyopneumothorax following CT-guided radiofrequency ablation for lung cancer with interstitial pneumonia. Acta Radiol Short Rep, 1, 2012 arsr.2012.110014.
31. Kashima, M., Yamakado, K., Takaki, H., et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: A single center's experiences. AJR Am J Roentgenol 197 (2011), W576–W580.
32. Okuma, T., Matsuoka, T., Hamamoto, S., et al. Percutaneous computed tomography-guided radiofrequency ablation of lung tumors complicated with idiopathic interstitial pneumonia. Ann Thorac Surg 87 (2009), 948–950.
33. Nakajima, Y., Akiyama, H., Kinoshita, H., et al. The importance of determining surgical indications in cases of lung cancer and interstitial pneumonia with multiple intrapulmonary lymph nodes. Int J Surg Case Rep 18 (2016), 5–8.
34. Mimae, T., Suzuki, K., Tsuboi, M., et al. Surgical outcomes of lung cancer in patients with combined pulmonary fibrosis and emphysema. Ann Surg Oncol 22 (2015), S1371–S1379.
35. Fukui, M., Suzuki, K., Oh, S., et al. Distribution of interstitial pneumonia: A new radiological predictor of 90-day mortality after resection of lung cancer. Surg Today 46 (2016), 66–73.
36. Khan, K.A., Kennedy, M.P., Moore, E., et al. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung 193 (2015), 71–77.
37. Sato, T., Watanabe, A., Kondo, H., et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg 149 (2015), 64–69 70.e61-62.
38. Yamazaki, M., Ishikawa, H., Kunii, R., et al. A combination of preoperative CT findings and postoperative serum CEA levels improves recurrence prediction for stage I lung adenocarcinoma. Eur J Radiol 84 (2015), 178–184.
39. Ito, H., Nakayama, H., Yokose, T., et al. Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection. Asian Cardiovasc Thorac Ann 22 (2014), 948–954.
40. Lee, T., Park, J.Y., Lee, H.Y., et al. Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival. Respir Med 108 (2014), 1549–1555.
41. Inoue, T., Hayama, M., Kobayashi, S., et al. Lung cancer complicated with IgG4-related disease of the lung. Ann Thorac Cardiovasc Surg 20 Suppl (2014), 474–477.
42. Fiorelli, A., Accardo, M., Vicidomini, G., et al. LigaSure meets endobronchial valve in a case of lung cancer with pneumoconiosis. Transl Lung Cancer Res 2 (2013), 308–310.
43. Maniwa, T., Isaka, M., Nakagawa, K., et al. Chest-tube drainage is a sign of acute exacerbation of interstitial lung disease associated with lung cancer. Surg Today 43 (2013), 408–411.
44. Mizuno, Y., Iwata, H., Shirahashi, K., et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 41 (2012), e161–e165.
45. Yano, M., Sasaki, H., Moriyama, S., et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg 14 (2012), 146–150.
46. Iyoda, A., Jiang, S.X., Amano, H., et al. Prediction of postoperative exacerbation of interstitial pneumonia in patients with lung cancer and interstitial lung disease. Exp Ther Med 2 (2011), 1073–1076.
47. Saito, Y., Kawai, Y., Takahashi, N., et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg 92 (2011), 1812–1817.
48. Kanzaki, M., Kikkawa, T., Maeda, H., et al. Acute exacerbation of idiopathic interstitial pneumonias after surgical resection of lung cancer. Interact Cardiovasc Thorac Surg 13 (2011), 16–20.
49. Spina, D., Ambrosio, M.R., Rocca, B.J., et al. Rheumatoid nodule and combined pulmonary carcinoma: Topographic correlations: A case report and review of the literature. Histol Histopathol 26 (2011), 351–356.
50. Isobe, K., Hata, Y., Sakamoto, S., et al. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology 15 (2010), 88–92.
51. Suzuki, H., Sekine, Y., Yoshida, S., et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 41 (2011), 914–921.
52. Shintani, Y., Ohta, M., Iwasaki, T., et al. Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer. Gen Thorac Cardiovasc Surg 58 (2010), 182–185.
53. Akiba, T., Marushima, H., Kawahara, H., et al. Video-assisted thoracic surgery for patients with lung cancer and interstitial pneumonia. Ann Thorac Cardiovasc Surg 16 (2010), 236–241.
54. Watanabe, A., Higami, T., Ohori, S., et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?. J Thorac Cardiovasc Surg 136 (2008), 1357–1363 1363.e1-2.
55. Mun, M., Kohno, T., Video-assisted thoracic surgery for clinical stage I lung cancer in octogenarians. Ann Thorac Surg 85 (2008), 406–411.
56. Yuksel, M., Ozyurtkan, M.O., Bostanci, K., et al. Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg 82 (2006), 336–338.
57. Koizumi, K., Hirata, T., Hirai, K., et al. Surgical treatment of lung cancer combined with interstitial pneumonia: The effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg 10 (2004), 340–346.
58. Fujimoto, T., Okazaki, T., Matsukura, T., et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: Surgical contraindication?. Ann Thorac Surg 76 (2003), 1674–1678 discussion 1679.
59. Martinod, E., Azorin, J.F., Sadoun, D., et al. Surgical resection of lung cancer in patients with underlying interstitial lung disease. Ann Thorac Surg 74 (2002), 1004–1007.
60. Kirishima, K., Satoh, H., Yamashita, Y.T., et al. Unilateral metachronous lung cancers in a patient with idiopathic pulmonary fibrosis. Oncol Rep 6 (1999), 763–765.
61. Goto, T., Maeshima, A., Oyamada, Y., et al. Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer. Int J Clin Oncol 19 (2014), 266–273.
62. Yamauchi, Y., Izumi, Y., Inoue, M., et al. Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS One, 6, 2011, e29053.
63. Hyzy, R., Huang, S., Myers, J., et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132 (2007), 1652–1658.
64. Samet, J.M., Does idiopathic pulmonary fibrosis increase lung cancer risk?. Am J Respir Crit Care Med 161 (2000), 1–2.
65. Wao, H., Mhaskar, R., Kumar, A., et al. Survival of patients with non-small cell lung cancer without treatment: A systematic review and meta-analysis. Syst Rev, 2, 2013, 10.
66. Detterbeck, F.C., Gibson, C.J., Turning gray: The natural history of lung cancer over time. J Thorac Oncol 3 (2008), 781–792.
67. Nanda, R.H., Liu, Y., Gillespie, T.W., et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer 121 (2015), 4222–4230.
68. Louie, A.V., Rodrigues, G., Hannouf, M., et al. Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis. Radiother Oncol 99 (2011), 161–165.
69. Collard, H.R., Ryerson, C.J., Corte, T.J., et al. Acute exacerbation of idiopathic pulmonary fibrosis: An international working group report. Am J Respir Crit Care Med 194 (2016), 265–275.
70. Gross, T.J., Hunninghake, G.W., Idiopathic pulmonary fibrosis. N Engl J Med 345 (2001), 517–525.
71. Anscher, M.S., Kong, F.M., Andrews, K., et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41 (1998), 1029–1035.
72. O'Kane, S., Ferguson, M.W., Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 29 (1997), 63–78.
73. Nobashi, T., Kubo, T., Nakamoto, Y., et al. FDG uptake in less affected lung field provides prognostic stratification in patients with interstitial lung disease. J Nucl Med 57 (2016), 1899–1904.
74. Petit, S.F., van Elmpt, W.J., Oberije, C.J., et al. [(1)(8)F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys 81 (2011), 698–705.
75. Castillo, R., Pham, N., Ansari, S., et al. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiat Oncol, 9, 2014, 74.
76. Iwata, T., Yoshida, S., Fujiwara, T., et al. Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis. Ann Thorac Surg 102 (2016), 1905–1910.
77. Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.